Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice

References

• AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498–505
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–79
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study (CIGTS) comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943–53
   PubMed Web of Science ®Google Scholar
• Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications. Surv Ophthalmol 2002;47:63–73
   Google Scholar
• Woodward DF, Gil DW. The inflow and outflow of antiglaucoma drugs. Trends Pharmacol Sci 2004;25:238–41
   PubMed Web of Science ®Google Scholar
• Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 2007;12:313–27
   PubMed Web of Science ®Google Scholar
• Scharrer A, Ober M. Metipranolol 0.1% and pilocarpine 2% as a fixed combination compared to each substance alone in the treatment of glaucoma. A controlled, randomized clinical study comparing the intraindividual effects and tolerance. Klin Monatsbl Augenheilkd 1986;189: 450–5
   Google Scholar
• Soderstrom MB, Wallin O, Granstrom PA, Thorburn W. Timolol-pilocarpine combined vs timolol and pilocarpine given separately. Am J Ophthalmol 1989;107:465–70
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components [Dorzolamide-Timolol Study Group]. Ophthalmology 1998;105: 1936–44
   PubMed Web of Science ®Google Scholar
• Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893–9
   Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1–7
   PubMed Web of Science ®Google Scholar
• Craven ER, Walters TR, Williams R, et al.; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21: 337–48
   Google Scholar
• Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17: 53–62
   Google Scholar
• Leske MC, Heijl A, Hussein M, et al.; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56
   Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd ed. DOGMA Savona, Italy, 2003. Available at: http://www.eugs.org/ebook.asp [accessed 27 July 2007]
   Google Scholar
• American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2005. Available at: www.aao.org/ppp [accessed July 2007]
   Google Scholar
• Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007;114:1599–606
   Google Scholar
• Owen CG, Carey IM, De Wilde S, et al. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol 2006;90:861–8
   PubMed Web of Science ®Google Scholar
• Goldberg I. Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy. Br J Ophthalmol 2002;86:691–2
   PubMed Web of Science ®Google Scholar
• Anton A. Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 1. Br J Ophthalmol 2002;86:692–3
   PubMed Web of Science ®Google Scholar
• Skuta GL. Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 2. Br J Ophthalmol 2002;86:693–4
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg 1995;26:233–6
   PubMedGoogle Scholar
• Konstas AGP, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000;14:752–6
   PubMed Web of Science ®Google Scholar
• Olthoff CMG, Schouten JSAG, van de Borne BW, Webers CAB. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2005;112:953–61
   Google Scholar
• Buller AJ, Morgan LH, Hercules BL. Patients prefer once-daily glaucoma drops. Graefe’s Arch Clin Exp Ophthalmol 2007;245:293–4
   PubMed Web of Science ®Google Scholar
• Forsman E, Kivelä T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 2007;16:313–9
   PubMed Web of Science ®Google Scholar